MA53572A1 - Procédés de production et formes cristallines d'un inhibiteur mdm2 - Google Patents

Procédés de production et formes cristallines d'un inhibiteur mdm2

Info

Publication number
MA53572A1
MA53572A1 MA53572A MA53572A MA53572A1 MA 53572 A1 MA53572 A1 MA 53572A1 MA 53572 A MA53572 A MA 53572A MA 53572 A MA53572 A MA 53572A MA 53572 A1 MA53572 A1 MA 53572A1
Authority
MA
Morocco
Prior art keywords
production processes
crystal forms
mdm2 inhibitor
intermediates
chlorophenyl
Prior art date
Application number
MA53572A
Other languages
English (en)
French (fr)
Inventor
Matthew Bio
Sebastien Caille
Brian Cochran
Yuanqing Fang
Brian Fox
Brian Lucas
Lawrence Mcgee
Filisaty Vounatsos
Sean Wiedemann
Sarah Wortman
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53572(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA53572A1 publication Critical patent/MA53572A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epoxy Compounds (AREA)
MA53572A 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2 MA53572A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361833196P 2013-06-10 2013-06-10
PCT/US2014/041594 WO2014200937A1 (en) 2013-06-10 2014-06-09 Processes of making and crystalline forms of a mdm2 inhibitor

Publications (1)

Publication Number Publication Date
MA53572A1 true MA53572A1 (fr) 2021-10-29

Family

ID=51063849

Family Applications (3)

Application Number Title Priority Date Filing Date
MA38714A MA38714A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2
MA53572A MA53572A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2
MA43288A MA43288B1 (fr) 2013-06-10 2015-12-23 Procédés de production et formes cristallines d'un inhibiteur mdm2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA38714A MA38714A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA43288A MA43288B1 (fr) 2013-06-10 2015-12-23 Procédés de production et formes cristallines d'un inhibiteur mdm2

Country Status (38)

Country Link
US (10) US9376386B2 (OSRAM)
EP (2) EP3008039B1 (OSRAM)
JP (5) JP6998655B2 (OSRAM)
KR (4) KR20240159641A (OSRAM)
CN (3) CN110003092A (OSRAM)
AP (1) AP2015008891A0 (OSRAM)
AR (3) AR096582A1 (OSRAM)
AU (5) AU2014278428B2 (OSRAM)
BR (2) BR122020003153B1 (OSRAM)
CA (4) CA2914723C (OSRAM)
CL (3) CL2015003589A1 (OSRAM)
CR (2) CR20210290A (OSRAM)
CY (1) CY1123661T1 (OSRAM)
DK (1) DK3008039T3 (OSRAM)
EA (3) EA202091612A1 (OSRAM)
ES (1) ES2851023T3 (OSRAM)
HR (1) HRP20202065T1 (OSRAM)
HU (1) HUE053047T2 (OSRAM)
IL (4) IL297860A (OSRAM)
JO (2) JOP20200296A1 (OSRAM)
LT (1) LT3008039T (OSRAM)
MA (3) MA38714A1 (OSRAM)
MX (2) MX379872B (OSRAM)
MY (2) MY205257A (OSRAM)
NZ (1) NZ714821A (OSRAM)
PE (2) PE20210153A1 (OSRAM)
PH (2) PH12020550916A1 (OSRAM)
PL (1) PL3008039T3 (OSRAM)
PT (1) PT3008039T (OSRAM)
RS (1) RS61192B1 (OSRAM)
SG (2) SG10201801402XA (OSRAM)
SI (1) SI3008039T1 (OSRAM)
SM (1) SMT202100013T1 (OSRAM)
TN (1) TN2015000521A1 (OSRAM)
TW (3) TWI649306B (OSRAM)
UA (2) UA121301C2 (OSRAM)
UY (2) UY40179A (OSRAM)
WO (1) WO2014200937A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
JOP20200296A1 (ar) * 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
KR102305351B1 (ko) 2013-11-11 2021-09-24 암젠 인크 암의 치료를 위한, mdm2 억제제 및 하나 이상의 추가적 약제학적 활성 제제를 포함하는 조합 요법
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
IL319432A (en) * 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
EP3801476A4 (en) * 2018-05-25 2022-07-06 Kartos Therapeutics, Inc. METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS
AU2019327555B2 (en) * 2018-08-31 2025-01-16 Amgen, Inc. Processes for preparing a MDM2 inhibitor
CN110963958B (zh) * 2018-09-30 2025-10-10 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
WO2021236474A1 (en) * 2020-05-22 2021-11-25 Merck Sharp & Dohme Corp. Novel processes for preparing conjugates of the il-2 protein
KR20230058124A (ko) 2020-08-27 2023-05-02 오츠카 세이야쿠 가부시키가이샤 Mdm2 길항제를 사용하는 암 치료를 위한 생체표지자
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
US12054449B2 (en) 2021-08-05 2024-08-06 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate crystalline form and method for manufacturing the same
EP4382509A4 (en) * 2021-08-05 2025-08-27 Bio Pharm Solutions Co Ltd CRYSTALLINE FORM OF PHENYLCARBAMATE AND PROCESS FOR ITS PREPARATION
WO2023039161A1 (en) * 2021-09-09 2023-03-16 Kartos Therapeutics Methods of treating cancer dependent on myc gene expresssion
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN115925589A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钙盐及其制备方法
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483213A (en) * 1947-06-14 1949-09-27 American Cyanamid Co Alpha naphthalene sulfonic anhydride
GB1016828A (en) 1961-11-13 1966-01-12 Mcneilab Inc Substituted morpholines and process for preparing same
US3518236A (en) * 1967-07-20 1970-06-30 Uniroyal Inc Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives
DE3246148A1 (de) 1982-12-14 1984-06-14 Troponwerke GmbH & Co KG, 5000 Köln Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2604472B2 (ja) 1989-07-12 1997-04-30 株式会社クラレ 重合性組成物
WO1995023135A1 (en) 1991-03-07 1995-08-31 Fisons Corporation Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
JP3741441B2 (ja) 1994-08-19 2006-02-01 アボツト・ラボラトリーズ エンドセリン・アンタゴニスト
PT885215E (pt) 1996-02-13 2006-08-31 Abbott Lab Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
US6159990A (en) 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
IL134175A0 (en) 1997-08-04 2001-04-30 Abbott Lab Endothelin antagonists
AU1910299A (en) 1997-12-18 1999-07-05 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries
US6770658B2 (en) 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7052545B2 (en) * 2001-04-06 2006-05-30 California Institute Of Technology High throughput screening of crystallization of materials
US7195670B2 (en) * 2000-06-27 2007-03-27 California Institute Of Technology High throughput screening of crystallization of materials
DE19951418A1 (de) * 1999-10-26 2001-05-03 Merck Patent Gmbh Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
WO2002017912A1 (en) 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
WO2002042731A2 (en) * 2000-11-20 2002-05-30 Parallel Synthesis Technologies, Inc. Methods and devices for high throughput crystallization
WO2002060894A2 (en) 2001-01-30 2002-08-08 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
CA2446380A1 (en) 2001-05-08 2002-11-14 Yale University Proteomimetic compounds and methods
WO2002094787A1 (en) 2001-05-23 2002-11-28 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
EP1458380B1 (en) 2001-12-18 2008-03-19 F.Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
US6860940B2 (en) * 2002-02-11 2005-03-01 The Regents Of The University Of California Automated macromolecular crystallization screening
US6916833B2 (en) * 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
RU2006144811A (ru) 2004-05-18 2008-06-27 Ф.Хоффманн-Ля Рош Аг (Ch) Новые цис-имидазолины
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
JP2007297283A (ja) 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
MX2007004551A (es) 2004-10-18 2007-05-23 Amgen Inc Compuestos tiadiazol y metodos de uso.
EP1854795B1 (en) 2005-02-18 2016-06-01 Mitsubishi Tanabe Pharma Corporation Salt of a proline derivative, solvate thereof, and production method thereof
TWI314552B (en) 2005-03-16 2009-09-11 Hoffmann La Roche Novel cis-2,4,5-triaryl-imidazolines,their use as anti-cancer medicaments and their manufacture process
PL1871368T3 (pl) 2005-04-04 2011-12-30 Eisai R&D Man Co Ltd Związki dihydropirydynowe do zastosowania w chorobach neurodegeneracyjnych i demencji
US20090298814A1 (en) 2005-06-07 2009-12-03 Ramot At Tel Aviv Univeristy Ltd Novel salts of conjugated psychotropic drugs and processes of preparing same
US7893268B2 (en) 2005-07-27 2011-02-22 University Of Toledo Epithiolone analogues
AU2006319248B2 (en) 2005-12-01 2012-09-27 F.Hoffman-La Roche Ag 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents
BRPI0706621A2 (pt) 2006-01-18 2011-04-05 Amgen Inc composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
WO2008005268A1 (en) 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
AU2007275805A1 (en) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
WO2008021338A2 (en) 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
US20080045560A1 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
PL2139882T3 (pl) 2007-03-23 2014-05-30 Amgen Inc 3-podstawione pochodne chinoliny lub chinoksaliny i ich zastosowanie jako inhibitorów 3-kinazy fosfatydyloinozytolu (pi3k)
CA2680783C (en) 2007-03-23 2012-04-24 Amgen Inc. Heterocyclic compounds and their uses
DK2137186T3 (en) 2007-03-23 2016-04-18 Amgen Inc Heterocyclic compounds and their uses
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (en) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
CN101809002B (zh) 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
CA2693473A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
WO2009011880A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
EP2183232B1 (en) 2007-08-02 2013-03-06 Amgen, Inc Pi3 kinase modulators and methods of use
MX2010003868A (es) 2007-10-09 2010-04-27 Hoffmann La Roche Cis-imidazolinas quirales.
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
EP2222296A2 (en) 2007-12-26 2010-09-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists and zonisamide for epilepsy
CA2718959A1 (en) 2008-03-21 2009-09-24 Chlorion Pharma, Inc. Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain
AU2009260447B2 (en) 2008-05-30 2012-03-29 Amgen Inc. Inhibitors of PI3 kinase
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
WO2010030704A2 (en) 2008-09-10 2010-03-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
AR073578A1 (es) 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
AU2009294673B2 (en) 2008-09-18 2014-08-14 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
WO2010083246A1 (en) 2009-01-15 2010-07-22 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
JP2012518037A (ja) 2009-02-18 2012-08-09 アムジエン・インコーポレーテツド ｍＴＯＲキナーゼ阻害剤としてのインドール／ベンゾイミダゾール化合物
US8729074B2 (en) 2009-03-20 2014-05-20 Amgen Inc. Inhibitors of PI3 kinase
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
EP2430013B1 (en) 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
EP2445886B1 (en) 2009-06-25 2016-03-30 Amgen, Inc 4-aminoquinoline derivatives as pi3k inhibitors
CA2781865A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
EP2445898A2 (en) 2009-06-25 2012-05-02 Amgen, Inc 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
JP2012531436A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用
MX2012002420A (es) 2009-08-26 2012-06-27 Novartis Ag Compuestos de heteroarilo tetra-sustituidos y su uso como moduladores de mdm2 y/o mdm4.
EP2486044A2 (en) 2009-10-09 2012-08-15 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
TW201137923A (en) * 2010-02-10 2011-11-01 Halcyon Molecular Inc Aberration-correcting dark-field electron microscopy
IT1399923B1 (it) 2010-05-11 2013-05-09 Cbb Net S A Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN102153557B (zh) 2011-01-21 2013-03-20 中国科学院上海有机化学研究所 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途
WO2012147953A1 (ja) * 2011-04-28 2012-11-01 大塚化学株式会社 アゾジカルボンアミドの新規製造法
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
CN103373951B (zh) * 2012-04-28 2016-03-09 上海医药工业研究院 一种拉帕替尼中间体的制备方法
CA2901696C (en) 2013-02-19 2021-04-13 Amgen Inc. Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
MX368703B (es) 2013-02-28 2019-10-11 Amgen Inc Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط

Also Published As

Publication number Publication date
MA43288A1 (fr) 2020-04-30
KR20210121270A (ko) 2021-10-07
KR20230019216A (ko) 2023-02-07
WO2014200937A1 (en) 2014-12-18
US9623018B2 (en) 2017-04-18
EP3008039B1 (en) 2020-11-11
SG10201801402XA (en) 2018-04-27
CA3115609A1 (en) 2014-12-18
AU2018260844A1 (en) 2018-11-22
BR112015031004B1 (pt) 2022-09-20
CA3201958A1 (en) 2014-12-18
ES2851023T3 (es) 2021-09-02
EP3805232A1 (en) 2021-04-14
US9855259B2 (en) 2018-01-02
CL2015003589A1 (es) 2016-06-17
EA201592305A1 (ru) 2016-05-31
CA3200532A1 (en) 2014-12-18
US20220280496A1 (en) 2022-09-08
SI3008039T1 (sl) 2021-03-31
UA129695C2 (uk) 2025-07-09
NZ753956A (en) 2020-12-18
PT3008039T (pt) 2021-01-13
AR096582A1 (es) 2016-01-20
PE20160113A1 (es) 2016-03-03
CY1123661T1 (el) 2022-03-24
JP2025084856A (ja) 2025-06-03
CR20160010A (es) 2016-02-04
US20160289243A1 (en) 2016-10-06
JP2023089126A (ja) 2023-06-27
AU2014278428A1 (en) 2015-11-26
AR132854A2 (es) 2025-08-06
US9801867B2 (en) 2017-10-31
EP3008039A1 (en) 2016-04-20
PH12020550916A1 (en) 2024-03-25
IL297860A (en) 2023-01-01
MY205257A (en) 2024-10-09
AU2020267169A1 (en) 2020-12-03
AP2015008891A0 (en) 2015-11-30
IL281807B (en) 2022-12-01
EA202091612A1 (ru) 2020-10-05
JP2020147573A (ja) 2020-09-17
JO3768B1 (ar) 2021-01-31
AU2018260844B2 (en) 2020-08-13
MY194848A (en) 2022-12-19
US20180092898A1 (en) 2018-04-05
JOP20200296A1 (ar) 2017-06-16
CR20210290A (es) 2021-07-23
MA43288B1 (fr) 2020-10-28
IL281807A (en) 2021-05-31
HRP20202065T1 (hr) 2021-02-19
US20160289190A1 (en) 2016-10-06
IL242622A0 (en) 2016-02-01
LT3008039T (lt) 2021-01-25
TWI698428B (zh) 2020-07-11
JP7263439B2 (ja) 2023-04-24
RS61192B1 (sr) 2021-01-29
TW201536743A (zh) 2015-10-01
NZ714821A (en) 2020-10-30
IL242622B (en) 2019-06-30
BR122020003153B1 (pt) 2022-09-27
TW201922705A (zh) 2019-06-16
US20160264526A1 (en) 2016-09-15
JP2021130685A (ja) 2021-09-09
TWI791153B (zh) 2023-02-01
MX2019012007A (es) 2019-11-11
SMT202100013T1 (it) 2021-03-15
US20200281912A1 (en) 2020-09-10
CA2914723A1 (en) 2014-12-18
US20160289178A1 (en) 2016-10-06
PH12015502705B1 (en) 2022-04-27
DK3008039T3 (da) 2021-01-04
JP6998655B2 (ja) 2022-02-04
PH12015502705A1 (en) 2016-03-14
CN105358530A (zh) 2016-02-24
UY35605A (es) 2015-01-30
TWI649306B (zh) 2019-02-01
HUE053047T2 (hu) 2021-06-28
PE20210153A1 (es) 2021-01-26
CA2914723C (en) 2021-06-15
UY40179A (es) 2023-04-14
CN110003092A (zh) 2019-07-12
KR20240159641A (ko) 2024-11-05
CN110627708A (zh) 2019-12-31
AU2014278428B2 (en) 2018-11-15
AU2022271425B2 (en) 2024-06-13
MX2015016856A (es) 2016-04-07
IL266504A (en) 2019-07-31
JP2016528179A (ja) 2016-09-15
JP6891322B2 (ja) 2021-06-18
AR119727A2 (es) 2022-01-05
CA3115609C (en) 2023-08-08
AU2024216533A1 (en) 2024-09-19
EA031254B1 (ru) 2018-12-28
SG11201509896VA (en) 2016-01-28
CL2019000056A1 (es) 2019-05-03
US9757367B2 (en) 2017-09-12
US9376386B2 (en) 2016-06-28
CL2021000566A1 (es) 2021-09-03
US20230301974A1 (en) 2023-09-28
US20140364455A1 (en) 2014-12-11
US20160287570A1 (en) 2016-10-06
MX379872B (es) 2025-03-11
UA121301C2 (uk) 2020-05-12
KR20160018576A (ko) 2016-02-17
MA38714A1 (fr) 2017-10-31
AU2020267169B2 (en) 2022-08-25
TW202035370A (zh) 2020-10-01
AU2022271425A1 (en) 2022-12-22
TN2015000521A1 (en) 2017-04-06
IL281807B2 (en) 2023-04-01
BR112015031004A2 (pt) 2020-05-12
IL266504B (en) 2021-04-29
PL3008039T3 (pl) 2021-04-19
EA201891642A1 (ru) 2019-08-30

Similar Documents

Publication Publication Date Title
MA43288A1 (fr) Procédés de production et formes cristallines d'un inhibiteur mdm2
MX2015005015A (es) Inhibidores heteroarilo de pde4.
MX347257B (es) Solido de gamma-carbolinas fusionadas con heterociclos substituidos.
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
MA41607A (fr) Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
EA201300604A1 (ru) Соединения, предназначенные для лечения респираторно-синцитиальных вирусных инфекций
MA35016B1 (fr) Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt
UA111198C2 (uk) Похідні 1-феніл-2-піридинілалкільних спиртів як інгібітори фосфодіестерази
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
EA201071367A1 (ru) Соли соединений ингибиторов вич
EA201390336A1 (ru) Способ получения промежуточного соединения для синтеза лекарственного средства
WO2010036640A3 (en) Compounds for the treatment of inflammatory disorders
EA201170736A1 (ru) Синтез и новые солевые формы (r)-3-((e)-2-(пирролидин-3-ил)винил)-5-(тетрагидропиран-4-илокси) пиридина
DK1926732T3 (da) Fremgangsmåde til fremstillingen af carbapenemforbindelser
EA202190632A1 (ru) Способы получения ингибитора mdm2
WO2010129848A3 (en) 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxamides
MX2016002763A (es) Formas cristalinas de un derivado de pirrolidona util en el tratamiento de la enfermedad de alzheimer y preparacion de las mismas.
IN2013MU02719A (OSRAM)